Safety board clears TxCell to restart Ovasave study that was halted last year

By Gareth Macdonald contact

- Last updated on GMT

iStock/StanislavSalamanov
iStock/StanislavSalamanov
TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.

The study – named CATS29​ – stopped last year​ after regulator ANSM (Agence nationale de sécurité du medicament) raised concerns about the potential risk of microbial contamination at a manufacturing facility in Besancon where Ovasave was being produced.

Since then TxCell has hired contract manufacturers - Caladrius Biosciences’ subsidiary PCT in the US and MaSTherCell in Belgium – and amended the trial protocol.

In addition, the data and safety monitoring board (DSMB) overseeing CATS29 conducted a review of all available data from previously treated patients.

A spokeswoman for TxCell told us approval to restart study was granted by European authorities through the Voluntary Harmonisation Procedure (VHP) based on the DSMB's recommendations.

She added that: "The DSMB is made up of four independent experts in the field, using unblinded data​."

TxCell plans to resume CATs29 as soon as possible and expects top-line data within 21 months of the restart.

Ovasave

The news follows just a few months after TxCell regained full rights to Ovasave from cell therapy development firm Trizell.

Trizell had been working on Ovasave – including running the CATS29 study - since January 2014 when TxCell and partner Ferring Pharmaceuticals handed over development rights.

However, last December TxCell paid Trizell €15m ($15.9m) to regain full rights to the product. At the time TxCell outlined how it would modify the trial protocol.

The firm said while it would retain the primary endpoint of a Crohn's disease activity index (CDAI) response to a 1 million cell dose of the product vs placebo it would omit the dose-ranging arms of the trial.

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars